Pharos iBio Selected as IR Pitching Company at "Bio China 2026"

Introducing Achievements in Rasnolitinib and PHI-501 Development
Highlighting Case Studies of AI Drug Discovery Platform Utilization

Pharos iBio, an AI-based new drug development specialist company, announced on March 9 that it will participate in "Bio China 2026," held from the 12th to the 14th in Jiangsu Province, China, and deliver IR presentations targeting global pharmaceutical and biotech companies.

At this event, Pharos iBio plans to focus on the development achievements of Rasnolitinib, an acute myeloid leukemia treatment, and "PHI-501," a therapeutic for refractory solid tumors, while seeking strategic partnership opportunities such as technology transfer and joint research and development with major global pharmaceutical companies, including those in China. In addition, the company will highlight the development status of its next-generation menin inhibitor, PHI-601, as well as showcase the strengths and case studies of its AI drug discovery platform, Chemiverse.

Pharos I Bio, an AI-based drug development specialist company, will participate in "Bio China 2026," held in Jiangsu Province, China, from the 12th to the 14th, to conduct IR presentations targeting global pharmaceutical and biotechnology companies. Pharos I Bio

Pharos iBio aims to expand its network in the Chinese market and strengthen its global business competitiveness based on AI-driven drug discovery by promoting one-on-one partnering with global pharmaceutical giants, including local pharmaceutical companies.

Kyutae Kim, Head of Pharos iBio Australia, said, "Through this event, we will actively share the clinical value and marketability of our key pipelines and discuss possible collaborations for global commercialization."

This content was produced with the assistance of AI translation services.